Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2026)
Enanta Pharmaceuticals (ENTA) reported Gains from Sales and Divestitures of $148000.0 for Q1 2026, up 117.65% on a YoY basis from $68000.0 in Q1 2025, and up 117.65% quarter-over-quarter from $68000.0 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Gains from Sales and Divestitures for 10 years, with the latest figure at $148000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 117.65% year-over-year to $148000.0; the trailing twelve-month figure through Mar 2026 stood at $148000.0 (up 117.65% YoY), and the FY2023 full-year result was $70000.0, up 1300.0% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $148000.0, up from $68000.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $148000.0 in Q1 2026, with the low at $5000.0 in Q3 2022.
- Historically, Gains from Sales and Divestitures has averaged $75583.3 across 5 years, with a median of $69000.0 in 2023.
- Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures tumbled 88.89% — and 2023, when it surged 1300.0%.
- Enanta Pharmaceuticals' Gains from Sales and Divestitures stood at $56000.0 in 2022, then climbed by 25.0% to $70000.0 in 2023, then surged by 105.71% to $144000.0 in 2024, then plunged by 52.78% to $68000.0 in 2025, then soared by 117.65% to $148000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $148000.0 (Q1 2026), $68000.0 (Q1 2025), and $144000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148,000.00 |
| Mar 31, 2026 | 148,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Jun 30, 2024 | 116,000.00 |
| Jun 30, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Mar 31, 2023 | 56,000.00 |
| Mar 31, 2023 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |